Alamar Biosciences Rises 7% on Strong Earnings & Expansion into CAR‑T Therapies
Alamar Biosciences surges 7.1% after fresh earnings guidance, fueling renewed confidence in its CAR‑T and bispecific antibody pipeline.
- ALAMAR BIOSCIENCES INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read